ArticleAmerican journal of cancer research2026
Incidence and risk factors of infections in lung cancer patients receiving immunotherapy combined with chemotherapy: a real-world retrospective study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This single-center, real-world retrospective cohort study assessed the incidence, risk factors, and clinical risk stratification of infections in lung cancer (LC) patients receiving immune checkpoint inhibitors (ICIs) combined with chemotherapy. This study comprised a cohort of 616 consecutive LC patients who received ICI-based chemotherapy during hospitalization between January 2020 and December 2025. LASSO regression followed by multivariable logistic regression was used to identify independent risk factors. Optimal cutoffs for score construction were determined using receiver operating characteristic (ROC) curve analysis combined with the Youden index, and internal validation was performed with 1,000 bootstrap resamples. The overall infection rate was 9.09% (56/616), with pulmonary infection being the most common site (64.29%), and gram-negative bacteria being most predominant (50.00%) Among culture-positive specimens, CRKP, MRSA, and CRPA accounted for 40.00%, 33.33%, and 25.00% of their respective species. Multivariable analyses identified ECOG performance status ≥2 (OR=3.993, 95% CI: 1.520-10.926, P=0.005), C-reactive protein (CRP) (OR=1.114, 95% CI: 1.079-1.159, P<0.05) as independent risk factors. In summary, infections appear to be a major complication in LC patients receiving ICIs combined with chemotherapy, often involving drug-resistant pathogens. A scoring system based on seven routinely available clinical parameters demonstrated good discrimination and internal stability in bootstrap validation, potentially aiding in the identification of high-risk patients for preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.